SALT LAKE CITY, UT -- (MARKET WIRE) -- March 20, 2007 -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it has completed enrollment of patients in its global Phase 3 clinical trial of Flurizan™ (tarenflurbil) in Alzheimer's disease.
